Abstract:

This investigation was conducted to determine the effects of chromium supplementation on metabolic status in diabetic patients with coronary heart disease (CHD). This randomized, double-blind, placebo-controlled trial was performed in 64 diabetic patients with CHD between October 2017 and January 2018. Patients were randomly divided into two groups to obtain either 200 μg chromium ( n = 32) or placebo ( n = 32) for 12 weeks. Chromium supplementation significantly reduced body weight (− 0.9 ± 1.6 vs. + 0.1 ± 0.8 kg, P = 0.001), BMI (− 0.4 ± 0.7 vs. + 0.1 ± 0.3 kg/m^2, P = 0.002), fasting glucose ( β − 11.03 mg/dL; 95% CI, − 18.97, − 3.09; P = 0.007), insulin ( β − 1.33 μIU/mL; 95% CI, − 1.90, − 0.76; P < 0.001), and insulin resistance ( β − 0.44; 95% CI, − 0.62, − 0.25; P < 0.001) and significantly increased insulin sensitivity ( β 0.007; 95% CI, 0.003, 0.01; P < 0.001) compared with the placebo. In addition, taking chromium led to a significant reduction in serum high-sensitivity C-reactive protein (hs-CRP) ( β − 0.49 mg/L; 95% CI, − 0.91, − 0.06; P = 0.02) and plasma malondialdehyde (MDA) levels ( β − 0.22 μmol/L; 95% CI, − 0.35, − 0.10; P = 0.001); also, a significant rise in total antioxidant capacity (TAC) ( β 84.54 mmol/L; 95% CI, 31.05, 138.02; P = 0.002) was observed in comparison with placebo. Additionally, chromium administration significantly reduced diastolic blood pressure (DBP) ( β − 5.01 mmHg; 95% CI, − 9.04, − 0.97; P = 0.01) compared with the placebo. Overall, the 12-week supplementation of chromium to diabetic patients with CHD had beneficial impacts on weight, BMI, glycemic control, hs-CRP, TAC, MDA, and DBP. Trial Registration www.irct.ir : http://www.irct.ir : IRCT20170513033941N30.